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Summary 
Objective: Human papillomavirus (HPV) DNA has been detected in the oral cavity of 
infants and breast cancer tissue, suggesting its vertical transmission through maternal 
milk. We determined whether HPV is detected in maternal milk and is vertically 
transmitted by breast feefing. 
Methods: Informed consent was obtained, and maternal milk samples (n = 80) were 
analyzed for high-risk HPV DNA. In 43 women, this DNA was measured in the uterine 
cervix. In women with positive samples, this DNA was measured in the oral cavities of 
their children. The domain including HPV E6 and E7 was amplified by polymerase 
chain reaction using consensus primers, and HPV serotype determined by 
electrophoresis after restriction enzyme digestion.  
Results: High-risk HPV-16 was detected in 2 of 80 samples (2.5%), and in these 2 cases, 
high-risk HPV was not detected in the uterine cervix or oral cavity of the child. 
Conclusion: The infection of HPV in maternal milk is rare (2/80), vertical transmission 
through maternal milk was not detected in this study (0/80). HPV infection through 
maternal milk may occur, but its likelihood is low. 
Introduction 
The role of HPV in the pathogenesis of human cancers has been studied, and two 
HPV genes are known to encode the oncoproteins E6 and E7. The E6 and E7 proteins of 
HPV16 and 18 have been demonstrated to be necessary to efficiently immortalize their 
natural host cells (Kaur et al., 1989). HPV types 16 and 18 are known to be 
carcinogenic, and HPV types 31 and 33 are also likely carcinogenic in human cervical 
and anogenital cancers (International Agency for Research on Cancer, 1995). 
Approximately 40 distinct HPV types are known to infect the genital tract, and 
epidemiological studies to date suggest that at least 14 of these, called oncogenic or 
high-risk types, are significantly associated with progression to invasive cervical cancer 
(Bosch et al., 1995). Most of these high-risk types are phylogenetically related to either 
HPV16 (31, 33, 35, 52 and 58) or HPV18 (39, 45, 59 and 68) (Chan et al., 1995). 
Evidence indicates that HPV can be present in breast tissue, and therefore may also be 
present in maternal milk. HPV replication in primary human mammary ductal epithelial 
cells has been demonstrated, and HPV types 16 and 18 can immortalize normal breast 
epithelium in vitro (Wazer et al., 1995). Contradictory results concerning HPV detection 
in breast carcinomas have been reported (Syrjänen & Syrjänen, 2000).  
Several viruses have been detected in human maternal milk, and some viruses 
such as HTLV-1 (human T-lymphotropic virus type 1) and HIV (human 
immunodeficiency virus) can infect newborns (Michie & Gilmour, 2001). HPV is 
known to infect the oral mucosa of infants (Wazer et al., 1995), and may also infect the 
epithelium of the nipple and areola (Syrjänen & Syrjänen, 2000). The Finnish HPV 
Family Study is a prospective follow-up cohort study started 1998 to evaluate the 
transmission modes of HPV between newborns and their parents (Rintala et al., 2005). 
In this study, HPV DNA was detected in 15% of the genital and 10% of the oral samples 
collected from infants at birth, reaching peaks of 18% and 21%, respectively, at 6 
months, and declining to 10% at 24 months (Rintala et al., 2005). However the infection 
of HPV in maternal milk has not been studied so far. Here we present the results of HPV 
DNA testing in breast milk samples collected 3–7 d after delivery and incidence of HPV 
infection of infant oral cavity, to establish vertical HPV transmission through milk.  
 
Materials and methods 
Subjects 
80 women who delivered at Tokushima University Hospital participated in this study. 
Informed consent was sought and obtained from all participants. With the approval of 
the Ethical Review Board of Tokushima University Hospital, 80 samples of maternal 
milk and 43 samples of uterine cervix were analyzed for high-risk HPV DNA. The 
mean age of mothers was 30.6 years (range, 19–42 years). In addition, the children of 
women with positive breast milk samples were examined for high-risk HPV DNA in the 
oral cavity at 15 months after birth, when their mothers finished nursing, to exclude the 
possibility of contamination by nursing. The children of women with positive cervical 
samples were also examined for high-risk HPV DNA in the oral cavity at 3 months after 
birth. 
Samples and DNA extraction 
At the hospital 3–7 d postpartum, each mother collected a 5-ml milk sample 
manually into a 15-ml plastic centrifuge tube after washing hands with disinfectant. 
This procedure was done separately from feeding the infant. Cervical scrapings were 
collected 1 month after delivery. Cervical samples were collected with a brush, and oral 
cavity samples with cotton swabs. The samples were immediately frozen and stored at 
-80ºC. For DNA extraction, samples were suspended in digestion buffer containing 
proteinase K, and subsequently handled and processed in the same manner described 
below. 
The milk samples were centrifuged for 20 min at 3500 rpm to pellet the cells, 
from which DNA was extracted. Great care was taken during handling to avoid any 
contamination between samples. The pellet was suspended in digestion buffer (100 mM 
Tris-HCL pH 8.0, 0.5 M EDTA, 10% SDS) containing 20 mg/ml of proteinase K 
(Sigma-Aldrich, USA) and incubated for 12 h at 37ºC. DNA was extracted in 
phenol/chloroform/isoamyl alcohol (25:24:1 v/v/v) and resuspended in 20 μl distilled 
water. DNA concentration was determined with a spectrophotometer at 260 nm.  
Polymerase chain reaction (PCR) 
PCR amplification was applied to the analysis of breast milk, cervical, and oral samples 
using the same method, as previously described (Watts et al.,1998). For PCR 
amplification, 0.5 μg extracted total DNA was used as a template. All PCR procedures 
were performed in a final volume of 50 μl under identical conditions. The first PCR 
amplification was performed with HPV E6 and E7 consensus primer pair (HPVpU-1M 
forward primer 5′-TGTCAAAAACCGTTGTGTCC-3′ and HPVpU-2R reverse primer 
5′-GAGCTGTCGCTTAATTGCTC-3′) (22.5 pmol each), using 1.25 U AmpliTaq DNA 
polymerase (TaKaRa Ex TaqTM ), PCR buffer (10×Ex Taq Buffer, Mg2+ concentration 
20 mM), dNTP mixture (200 μM). The PCR mixture was subjected to 30 cycles of 
amplification consisting of denaturation at 94ºC for 1 min, annealing at 54ºC for 45 s, 
and elongation at 72ºC for 1 min. The domain including HPV E6 and E7 was amplified 
by PCR with consensus primers (TaKaRa PCR Human Papillomavirus Typing Set), 
with which high-risk HPV-16, 18, 31, 33, 35, 52, and 58 can be amplified (Fujinaga et 
al., 1991). HPV type was determined by electrophoresis after restriction enzyme 
digestion (AvaII, AfaII, BglII, AccII, AvaI; Enzyme Set A, TaKaRa). To control for the 
quality of extracted DNA, the β-actin gene was first amplified with PCR in 32 milk 
and oral cavity samples using previously described primers (Dai et al., 2005), and the 
same amount of β-actin product was obtained for each sample by running the same 
volume of product on an agarose gel.  
 
Results 
Characteristics of the enrolled women are summarized in Table 1. The median age at 
delivery was 30.6 years (range, 19–42 years). The mean number of gravidities was 2.3 
(range, 1–7), and parity was 1.8 (range, 1–6). We initially tested the presence of 
high-risk HPV DNA in breast milk. High-risk HPV DNA was detected in 2 of 80 milk 
samples (2.5%) in the cellular compartment (Figure 1). Sequencing indicated that both 
HPV-positive samples contained HPV-16-DNA. The women with HPV DNA-positive 
maternal milk were both negative for high-risk HPV DNA in cervix, and they had no 
history of HPV-related disease (condylomata, cervical intraepithelial neoplasia, or 
cervical cancer) or mammary disease (Table 1).  
Table 2 summarizes the HPV types and prevalence in mothers and infants 
(specimens collected 3 or 15 months after birth). In cases of HPV DNA-positive 
maternal milk, HPV DNA was not detected throughout the buccal mucosa of children 
15 months after birth. In cases of HPV DNA-positive cervix, HPV DNA was not 
detected in the oral cavity of children 3 months after birth (Figure 1). All 4 patients with 
cervical HPV delivered by vaginal. β-actin was detected by PCR in all samples from 
children, indicating that these samples contained sufficient DNA for analysis. 
 
Discussion 
HPV types 16 and 18 are carcinogenic, and HPV types 31 and 33 are likely also 
carcinogenic, in human cervical and anogenital cancers (International Agency for 
Research on Cancer, 1995). Connections between HPV and breast cancer have also 
been reported (Di Lonard et al., 1992, Yu et al.,1999, Hennig et al., 1999, Liu et al., 
2001). Damin et al. detected HPV in 25 of 101 (24.75%) patients with breast cancer, 
and did not identify HPV in any of 41 benign lesions (20 patients with reduction 
mammoplasty and 21 with mammary fibroadenomas). The authors isolated HPV-16 
DNA in 14 patients (56%), HPV-18 in 10 patients (40%), and both serotypes in one 
patient (4%) (Damin et al., 2004).  
Vertical transmission of HPV has also been reported. In 1993, Fredericks and 
colleagues reported the transmission of HPV from mother to child in 8 of 11 women 
with genital genotypes of HPV in their cervical smears. The children had HPV of the 
same genotype in buccal mucosal cell samples, and one child whose mother had no 
HPV DNA detected in her cervical smears was also positive for HPV DNA (Fredericks 
et al., 1993). In 1994, Pakarian et al. found HPV DNA in buccal or genital swabs from 3 
of 11 infants born to women with HPV DNA-negative cervical swabs. In another study 
by Puranen et al., HPV DNA was found in 31 of 98 (31.6%) oral scrapings from 
children, 12 of whom were born to mothers negative for HPV DNA in uterine cervix 
(1996). Watts et al. reported positive specimens in 3 of 80 infants (4%) born to women 
with HPV DNA detected at 34 weeks’ gestation and 5 of 63 infants (8%) born to women 
without HPV DNA (1998). In these reports, HPV type was not always concordant 
between newborn and mother (Smith et al., 2004). In infants, HPV DNA was detected 
in 15% of genital and 10% of oral samples collected at birth, reaching peaks of 18% and 
21%, respectively, at 6 months, and declining to 10% at 24 months (Rintala et al., 2005). 
These findings suggest the possibility of vertical transmission through maternal milk, in 
addition to other infection pathways via the birth canal or the oral cavity of parents. 
The results of the present study support the possibility that HPV infection can 
occur through maternal milk. The origin of HPV DNA in the mother’s milk remains an 
interesting question. The cellular compartment of human milk contains epithelial cells 
as well as cells of the immune system. According to current opinion, HPV infects 
epithelial cells and multiplies locally at the site of entry on the skin or mucous 
membranes, and infection does not lead to viraemia. A suggestive clue comes from the 
observation by de Villiers et al. (2006) that HPV is present in cancers occurring in 
human nipple milk ducts, and that these cancers have the typical histological features of 
HPV-induced human cancers. This finding supports the view of a pathogenic 
mechanism involving HPV transfer in a retrograde fashion via nipple, areola, lactiferous 
ducts, and sinuses. 
Even when HPV infects the uterine cervix, it is thought to disappear naturally in 
about 90% of cases. Persistent infection is related to CIN or cervical cancer. In a similar 
manner, if HPV infection of a breast should occur through a nipple in a sexual encounter, 
HPV may be removed naturally in many cases, and persistent infection may be related 
to the malignant transformation of breast cancer. Although our results support the 
possibility of HPV infection through maternal milk, this phenomenon suggests that even 
if HPV is contagious temporarily to the oral mucosa of the child, it will also be removed 
naturally in many cases. This study indicates that the risk of HPV infection in maternal 
milk is low and vertical transmission of HPV via maternal milk is probably low.  
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Figure legend 
Figure 1 
Mother: PCR was performed using the primer pair HPVpu-1M/HPVpu2R. Lane 1: 
high-risk HPV positive control; lane 2: negative control; lane 3: milk sample (case 1: 
positive); and lane 4: milk sample (case 2: positive). Child: Lane 1: high-risk HPV 
positive control; lane 2: oral sample (case 1: negative); lane 4: oral sample (case 2: 
negative); lane 6: oral sample (case 3: negative); lane 8: oral sample (case 5: negative); 
lane 10: oral sample (case 6: negative); and lanes 3, 5, 7, 9, and 11: β-actin was 
amplified (cases 1, 2, 3, 5, and 6, respectively). 
 
 
Table1. Maternal characteristics at enrollment and HPV infection in 
maternal milk (N=80)
Maternal Characteristics No.   n=80 HR HPV-positive mothers in beast milk (%) n=2
Age
<25
25-34
35≤ 
7
55
18 
0 (0)
2 (3.6)
0 (0)
Gravidity
1
2 ≤
25
55 
2 (8.0)
0 (0)
Parity
1
2 ≤
34
46
2 (5.9)
0 (0)
Smoking
Never
Ever
73
7
2 (2.7)
0 (0)
HPV infection in cervix
Negative
Positive
No sample
39
4
37
2 (5.2)
0 (0)
0 (0)
HPV-related disease history
Never
CIN
79
1
2 (2.5)
0 (0)
Type of delivery 
Vaginal
Cesarean-section
60
20
1 (1.7)
1 (5.0)
Mammary disease history
Never
Mastitis
78
2
2 (2.6)
0 (0)
Table 2. HPV prevalence and types in mothers 
and infants
Case
Mother
Breast milk            Cervix
Baby            Complication
Oral
1 HPV16                      N N              EBV infection
2 HPV16                      N N
3 N                        HPV52 N
4 N                        HPV16 ー
5 N                    High-risk HPV N
6 N                    High-risk HPV N
“ー” = no sample available          N = negative
Oral = oral sample in 3 or15 months after birth
Breast milk = breast milk sample in 3-7days after delivery
Cervix = cervix sample in 1 month after delivery
